Advanced search
Publication Cover
ImmunoTargets and Therapy Volume 4, 2015 - Issue
Submit an article Journal homepage
175
Views
9
CrossRef citations to date
0
Altmetric
Review

Update on use of aldesleukin for treatment of high-risk metastatic melanoma

Rodabe N Amaria1 Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
,
Alexandre Reuben2 Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
,
Zachary A Cooper2 Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA;3 Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA
&
Jennifer A Wargo2 Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA;3 Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence[email protected]
Pages 79-89 | Published online: 07 Apr 2015

Citations (9)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Stephen K. Doberstein. (2019) Bempegaldesleukin (NKTR-214): a CD-122-biased IL-2 receptor agonist for cancer immunotherapy. Expert Opinion on Biological Therapy 19:12, pages 1223-1228.
Read now
Lars M Wagner & Val R Adams. (2017) Targeting the PD-1 pathway in pediatric solid tumors and brain tumors. OncoTargets and Therapy 10, pages 2097-2106.
Read now

Articles from other publishers (7)

Firas Hamdan & Vincenzo Cerullo. (2023) Cancer immunotherapies: A hope for the uncurable?. Frontiers in Molecular Medicine 3.
Crossref
Francesca Ragusa, Silvia Martina Ferrari, Giusy Elia, Sabrina Rosaria Paparo, Eugenia Balestri, Chiara Botrini, Armando Patrizio, Valeria Mazzi, Giovanni Guglielmi, Rudy Foddis, Claudio Spinelli, Salvatore Ulisse, Alessandro Antonelli & Poupak Fallahi. (2022) Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer. International Journal of Molecular Sciences 23:10, pages 5731.
Crossref
Piyu Parth Naik. (2021) Current Trends of Immunotherapy in the Treatment of Cutaneous Melanoma: A Review. Dermatology and Therapy 11:5, pages 1481-1496.
Crossref
Siddhartha Sood, Rahul Jayachandiran & Siyaram Pandey. (2021) Current Advancements and Novel Strategies in the Treatment of Metastatic Melanoma. Integrative Cancer Therapies 20, pages 153473542199007.
Crossref
Kylie Su Mei Yong, Zhisheng Her, Sue Yee Tan, Wilson Wei Sheng Tan, Min Liu, Fritz Lai, Shi Min Heng, Yong Fan, Kenneth Tou En Chang, Cheng-I Wang, Jerry Kok Yen Chan, Jianzhu Chen & Qingfeng Chen. (2020) Humanized Mouse as a Tool to Predict Immunotoxicity of Human Biologics. Frontiers in Immunology 11.
Crossref
Min Hwa Shin, Jiyoung Kim, Siyoung A. Lim, Jeongsoo Kim & Kyung-Mi Lee. (2020) Current Insights into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade. International Journal of Molecular Sciences 21:7, pages 2531.
Crossref
Hassan Sadozai, Thomas Gruber, Robert Emil Hunger & Mirjam Schenk. (2017) Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma. Frontiers in Immunology 8.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.